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Abstract. Inflammatory cytokines, matrix metalloproteinases 
(MMPs) and cyclooxygenase (COX)‑2 released from rheuma-
toid arthritis synovial fibroblasts (RASFs) are involved in the 
destruction of both articular bone and cartilage. Kaempferol 
has been reported to act as an antioxidant and anti‑inflam-
matory agent by inhibiting nitric oxide synthase and COX 
enzymes. The aim of the present study was to determine the 
effects of kaempferol on the interleukin‑1β (IL-1β)‑induced 
proliferation of RASFs and the production of MMPs, COX 
and prostaglandin E2 (PGE2) by RASFs. The proliferation 
of the RASFs stimulated with IL‑1β and treated with/without 
kaempferol was evaluated by CCK‑8 assay. The expression of 
MMPs, TIMP metallopeptidase inhibitor‑1 (TIMP‑1), COXs, 
PGE2 and that of intracellular MAPK signaling molecules, 
including p‑ERK, p‑p38, p‑JNK and nuclear factor‑κB (NF-κB) 
was examined by immunoblotting or semi‑quantitative reverse 
transcription‑polymerase chain reaction (RT‑PCR) and ELISA 
under the conditions described above. Kaempferol inhibited 
the proliferation of both unstimulated and IL‑1β‑stimulated 
RASFs, as well as the mRNA and protein expression of MMP‑1, 
MMP‑3, COX‑2 and PGE2 induced by IL‑1β. Kaempferol also 
inhibited the phosphorylation of ERK‑1/2, p38 and JNK, as 
well as the activation of NF‑κB induced by IL‑1β. These results 
indicate that kaempferol inhibits synovial fibroblast prolifera-
tion, as well as the production of and MMPs, COX‑2 and PGE2, 
which is involved in articular inflammation and destruction in 
rheumatoid arthritis (RA). Our data suggest that kaempferol 
may be a novel therapeutic agent for the treatment of RA.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory systemic 
disease of unknown etiology characterized by chronic 
synovitis with subsequent articular bone and cartilage destruc-
tion (1,2). Chronic inflammation with hyperplasia of synovial 
lining cells, including synovial fibroblasts, are the histological 
characteristics of RA. When activated, rheumatoid arthritis 
synovial fibroblasts (RASFs) play a key role in the pathogen-
esis of RA synovitis through proliferation and resultant pannus 
formation. Inflammatory cytokines, matrix metalloprotein-
ases (MMPs) and cyclooxygenase (COX)‑2 released from 
RASFs are involved in the destruction of articular bone and 
cartilage (1,2). On the basis that interleukin (IL)‑1β induces 
the proliferation of RASFs, resulting in the production of high 
levels of MMPs and prostaglandin E2 (PGE2), it has become a 
major target of biological therapy.
Flavonoids are natural polyphenols present in a wide 
variety of fruits and vegetables (3) and have a number of 
biological properties, such as antiviral (4), antitumor (5), anti-
oxidant (6) and anti‑inflammatory properties (7). Kaempferol 
(3,5,7,4'‑tetrahydroxy flavone), which is found in tea, propolis 
and grapefruit, is one of the most common dietary flavonoids (8). 
It has been used as a traditional therapeutic for a number of 
inflammatory disorders. Previous studies have demonstrated 
that kaempferol reduces lipopolysaccharide‑induced COX‑2 
levels in RAW 264.7 cells (9) and inhibits reactive oxygen 
species production through the inhibition of inducible nitric 
oxide synthase (iNOS) and tumor necrosis factor (TNF)‑α 
protein expression in aged gingival tissues (10). Kaempferol has 
also exhibited anti‑inflammatory effects through the inhibition 
of IL‑4 (11), COX‑2 and C‑reactive protein (CRP) expression 
and the downregulation of nuclear factor‑κB (NF-κB) in liver 
cells (12). Despite these anti‑inflammatory effects of kaemp-
ferol and the critical role of RASFs in RA pathogenesis, to our 
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knowledge, there are no studies to date on the effects of kaemp-
ferol on inflammatory reactions, including the production of 
MMPs, COX‑2 and PGE2 by RASFs.
In the present study, we investigated the effects of kaemp-
ferol on the production of pro‑inflammatory mediators, 
including MMPs, COX‑2 and PGE2 produced by RASFs and 
the proliferation of these cells, following stimulation with 
IL-1β. Intracellular signaling factors were evaluated to eluci-
date the mechanisms behind the effects of kaempferol. We 
demonstrate that kaempferol inhibits the IL‑1β‑induced prolif-
eration of RASFs and inflammatory reactions by inhibiting the 
activation of mitogen‑activated protein kinases (MAPKs) and 
NF-κB pathways in RASFs.
Materials and methods
Reagents and antibodies. Recombinant human IL‑1β was 
purchased from R&D Systems (Minneapolis, MN, USA) and 
kaempferol were obtained from Sigma‑Aldrich, Inc. (St. Louis, 
MO, USA) and dissolved in DMSO with a concentration 
of 100 mM stock solution. Monoclonal antibodies (mAbs) 
against COX‑2, MMP‑1, MMP‑3 and TIMP were purchased 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). 
mAbs against NF-κB (p65), IkBα, ERK, p‑ERK, JNK, p‑JNK, 
p38, p‑p38 and β‑actin were purchased from Cell Signaling 
Technology (Beverly, MD, USA). Fetal bovine serum (FBS) 
was obtained from Gibco BRL/Life Technologies (Grand 
Island, NY, USA).
Isolation and culture of RASFs. Synovial tissues were 
obtained at the time of total knee arthroplasty from patients 
who fulfilled the American College of Rheumatology Criteria 
for RA (13), as previously described (14). Synovial tissue 
was digested for 2 h with 0.25% (w/v) collagenase and was 
then suspended in RPMI‑1640 medium with 10% (v/v) FBS, 
100 U/ml of penicillin and 100 µg/ml of streptomycin. The 
cells were incubated at 37˚C in 5% CO2 for several days, after 
which the non‑adherent cells were removed. Synovial fibro-
blasts from passages 3‑7 were used for each experiment and 
were morphologically homogeneous and had the appearance 
of RASFs with typical fibroblastoid configuration under an 
inverse microscope. The purity of the cells was determined 
by flow cytometry using phycoerythrin (PE)‑conjugated 
anti‑Thy‑1 (CD90) or anti‑CD14 and fluorescein isothiocya-
nate (FITC)‑conjugated anti‑CD3 mAb (BD Pharmingen, San 
Diego, CA, USA). Informed consent was obtained from all 
patients, and the study protocol was approved by the Chonbuk 
National University Hospital Ethics Committee.
Cell viability analysis. Cell viability was determined by using 
the Cell Counting Kit‑8 (CCK‑8; Dojindo Laboratories, Japan) 
according to the manufacturer's instructions. CCK‑8 allows 
convenient assays using Dojindo's tetrazolium salt, 2‑(2‑ 
methoxy‑4‑nitrophenyl)‑3‑(4‑nitrophenyl)‑5‑(2,4‑disulfophenyl)‑ 
2H‑tetrazolium, monosodium salt (WST‑8), which produces a 
water‑soluble formazan dye upon bioreduction in the presence 
of an electron carrier, 1‑methoxy phenazinium methylsulfate 
(PMS) (15). CCK‑8 solution is added directly to the cells; no 
pre‑mixing of the components is required. CCK‑8 is a sensitive 
non‑radioactive colorimetric assay for determining the number 
of viable cells in cell proliferation and cytotoxicity assays. 
WST‑8 is bioreduced by cellular dehydrogenases to an orange 
formazan product that is soluble in tissue culture medium. The 
amount of formazan produced is directly proportional to the 
number of living cells. RASFs [1x105 cells/well in Dulbecco's 
modified Eagle's medium (DMEM) containing 10% (v/v) FCS 
in a 96‑well U‑bottom plate] were cultured in 200 µl medium/ 
well in the presence or absence of 1.0 ng/ml IL‑1β and/or 
kaempferol (100 µM) for 2 days according to the results of a 
dose‑dependent examination and a previous report (15), while 
the control RASFs were incubated in DMEM with DMSO. 
CCK‑8 (20 µl) was added to each well of the plate and the cells 
were incubated for 2‑3 h. The absorbance was measured at 
450 nm using a microplate reader to determine the cell viability 
in each well.
Analysis of apoptosis. To evaluate the effects of kaempferol 
on the apotosis of RASFs, RASFs were incubated in DMEM 
for 24 h with kaempferol (100 µM), while the control RASFs 
were incubated in DMEM with DMSO. The cells were then 
trypsinized and collected for the detection of apoptosis with 
an Annexin V‑FITC Apoptosis Detection kit according to the 
manufacturer's instructions. Briefly, the cells were washed 
twice with cold PBS and resuspended in 500 ml of binding 
buffer (10 mM HEPES‑NaOH pH 7.4, 140 mM NaCl, 2.5 mM 
CaCl2) at a concentration of 0.5x10
5 cells/ml. After the addition 
of 5 µl of Annexin V‑FITC solution and propidium iodide (PI; 
5 µl), the cells were incubated for 15 min at room temperature. 
The cells were analyzed using a flow cytometer (Beckman 
Coulter, Fullerton, CA, USA).
RNA isolation and semi-quantitative reverse transcrip-
tion-polymerase chain reaction (RT-PCR( of COX, MMPs 
and TIMP. Total RNA was extracted from the cultured RASFs 
using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) 
following the manufacturer's instructions. RNA (1 µg) was 
reverse‑transcribed using the Maxime RT Premix kit (iNtRON 
Biotechnology, Seoul, Korea). cDNA was amplified using the 
following primer sets: MMP‑1 sense, 5'‑GAA GGA GAT 
GAA GCA GCC CAG ATG T‑3' and antisense, 5'‑CAG TTG 
TGG CCA GAA AAC AGA AGT GAA A‑3'; MMP‑3 sense, 
5'‑GAC ACC AGC ATG AAC CTT GTT‑3' and antisense, 
5'‑GGA ACC GAG TCA GGA CTA TG‑3'; TIMP‑1 sense, 
5'‑CCT TCT GCA ATT CCG ACC TCG TC‑3' and antisense, 
5'‑CGG GCA GGA TTC AGG CTA TCT GG‑3'; COX‑2 
sense, 5'‑TCC TTG CTG TTC CCA CCC ATG‑3' and anti-
sense, 5'‑CAT CAT CAG ACC AGG CAC CAG‑3'; GAPDH 
sense, 5'‑AAA TCA AGT GGG GCG ATG CT‑3' and anti-
sense, 5'‑AGC TTC CCG TTC AGC TCA GG‑3'. PCR 
products were electrophoresed using 1% agarose gels and 
visualized by staining with ethidium bromide. Densitometric 
analysis was performed on the relative intensity of each band 
using the Multi Gauge software v3.0 (Fujifilm, Tokyo, Japan).
Immunoblotting. RASFs (1x106 cells) were seeded on 100‑mm 
culture dishes and harvested in phosphate‑buffered saline 
(PBS). After washing with PBS, cell pellets were lysed with 
the lysis buffer [20 mM HEPES, pH 7.2, 1% Triton X‑100, 
150 mM NaCl, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 
1 mM EDTA and 1 µg/ml aprotinin]. Following incubation for 
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30 min at 4˚C, cellular debris was removed by centrifugation 
at 100,000 x g for 30 min and the supernatants were analyzed 
by sodium dodecyl sulfate‑polyacrylamide gel electrophoresis 
(SDS‑PAGE). To determine membrane COX‑2 expression in 
RASFs, cell membranes were prepared from isolated RASFs 
as previously described (16). To determine NF-κB (p65) 
expression, nuclear extracts were prepared using a previ-
ously described method (14). To determine cytoplasmic IkBα 
expression, cytoplasmic extracts were prepared as previously 
described (14).
Protein concentration was determined using the Bio‑Rad 
protein assay reagent (Bio‑Rad Laboratories, Hercules, CA, 
USA). Samples (50 µg) were prepared with 4 vol of 0.5 M 
Tris buffer (pH 6.8) containing 4% SDS, 20% glycerol and 
0.05% bromophenol blue at 95˚C for 5 min. SDS‑PAGE was 
performed on a 10% slab gel. Proteins were transferred onto 
a nitrocellulose membrane. The membrane was washed in 
blocking buffer (10 mM Tris‑HCl pH 8.0, 150 mM NaCl, 5% 
fat‑free milk) for 60 min at room temperature with shaking 
and then washed with TBST (TBS, 0.01% Tween‑20). Primary 
antibodyies (10 µg/ml) against MMP‑1, MMP‑3, TIMP, COX‑2, 
ERK, p‑ERK‑1/2, p‑38, p‑p38 MAPK, JNK, p‑JNK, NF-κB 
(p65), IkBα and β‑actin were then added followed by incuba-
tion at 4˚C for 4 h. The secondary HRP‑conjugated antibody 
was goat anti‑mouse IgG (Santa Cruz Biotechnology, Inc.). 
Reactive proteins were detected by enhanced chemilumines-
cence (ECL; Amersham Life Sciences, Arlington Heights, IL, 
USA) using Fujifilm LAS‑3000 (Fujifilm).
Assay of PGE2 production. RASFs (1x104 cells) were grown 
in 25 cm2 tissue‑culture flasks for 48 h before treatment. After 
washing with PBS (pH 7.4), cells were pre‑treated with IL‑1β 
(1.0 ng/ml) or kaempferol (100 µM) at 37˚C for 48 h in DMEM 
containing 10% (v/v) FCS in an atmosphere of 5% CO2, while 
the control RASFs were incubated in DMEM with DMSO. The 
culture supernatant described above was collected at 2 days. 
The level of PGE2 in the medium was determined by ELISA 
(R&D Systems) in accordance with the instructions of the 
manufacturer.
Statistical analysis. All data are expressed as the means ± SD 
of the results of 3 experiments with different RASFs and all 
data were analyzed using SPSS 12.0 software. Group mean 
values were compared using the Student's t‑test or ANOVA 
where appropriate. P‑values <0.05 were considered to indicate 
statistically significant differences.
Results
Kaempferol inhibits the IL-1β-induced proliferation of RASFs. 
The effect of kaempferol on the growth ability of RASFs was 
initially evaluated. Cell proliferation was measured following 
treatment with IL‑1β for 3 days; IL‑1β is a well known potent 
growth‑promoting factor for RASFs (17). Cell proliferation 
was assayed as described in Materials and methods. IL‑1β 
increased the proliferation of RASFs in a dose‑dependent 
manner (from 0.1 to 10 ng/ml). To examine the effects of 
kaempferol on the IL‑1β‑induced proliferation of RASFs, 
kaempferol (100 µM) was added to the RASF cultures with/
without IL‑1β (1.0 ng/ml) for 2 days and the CCK‑8 assay was 
performed. IL‑1β significantly increased the proliferation of 
RASFs compared with the control cells cultured in DMSO 
without IL‑1β and kaempferol (P<0.05) (Fig. 1A). Kaempferol 
significantly inhibited the proliferation of RASFs treated with 
or without IL‑1β (P<0.05). Various doses of kaempferol (10, 
50, 100, 200 µM) were added to the RASF cultures with IL‑1β 
(1.0 ng/ml) for 2 days and CCK‑8 assay was performed. The 
inhibitory effects of kaempferol were significantly enhanced 
in a dose‑dependant manner (Fig. 1B).
Kaempferol induces the apoptosis of RASFs. To elucidate 
the underlying mechanisms by which kaempferol inhibits 
the IL‑1β‑induced proliferation of RASFs, the effects of 
kaempferol on the apoptosis of RASFs were examined by flow 
cytometry and staining with Annexin V and PI. The percentage 
of Annexin V‑positive cells was significantly increased in 
the RASFs treated with kaempferol compared with the cells 
cultured in DMEM with DMSO without kaempferol (P<0.05) 
(Fig. 2).
Figure 1. Interleukin‑1β (IL-1β) increases the proliferation of rheumatoid arthritis synovial fibroblasts (RASFs) in a dose‑dependent manner and kaempferol 
inhibits the IL‑1β‑induced proliferation of RASFs. (A) To determine the effects of kaempferol on the IL‑1β‑induced proliferation of RASFs, kaempferol 
(100 µM) was added to the RASF cultures with/without IL‑1β (1.0 ng/ml) for 3 days and CCK‑8 assay was performed. Kaempferol significantly inhibited the 
IL‑1‑induced proliferation of RASFs after 2‑3 days of culture (P<0.05). *P<0.05 vs. no IL‑1β and kaempferol (control), #P<0.05 vs. IL‑1β without kaemp ferol. 
(B) To determine the dose‑dependent effects of kaempferol on the IL‑1β‑induced proliferation of RASFs, various doses of kaempferol (10, 50, 100 and 200 µM) 
were added to the RASF cultures with IL‑1β (1.0 ng/ml) for 2 days and CCK‑8 assay was performed. Kaempferol inhibited the IL‑1β‑induced proliferation 
of RASFs in a dose‑dependent manner. *P<0.05 vs. no IL‑1β and kaempferol, #P<0.05 vs. IL‑1β without kaempferol, ##P<0.01 vs. IL‑1β without kaempferol.
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Effects of kaempferol on IL-1β-induced MMP, TIMP-1 and 
COX mRNA expression in RASFs. RT‑PCR was performed 
to determine the mRNA expression of MMP‑1, MMP‑3 and 
TIMP‑1 in the monocultured RASFs. RASFs were stimulated 
with IL‑1β (1.0 ng/ml) for 48 h in the presence or absence of 
kaempferol (100 µM). IL‑1β enhanced the mRNA expres-
sion of MMP‑1 and MMP‑3 in RASFs (P<0.05), but not that 
of TIMP‑1. Kaempferol inhibited the effects of IL‑1β on the 
mRNA expression of MMP‑1 and MMP‑3 (P<0.05) (Fig. 3A). 
IL-1β also enhanced the mRNA expression of COX‑2 in 
RASFs (P<0.01), but not that of COX‑1 (data not shown). 
Kaempferol inhibited the IL‑1β‑induced COX‑2 mRNA 
expression (P<0.05) (Fig. 3A). Kaempferol also significantly 
decreased the mRNA expression of MMP‑1, MMP‑3 and 
COX‑2 compared with the control cells cultured in DMSO 
without IL‑1β and kaempferol (P<0.05).
Figure 2. Kaempferol induces the apoptosis of rheumatoid arthritis synovial fibroblasts (RASFs). To determine the exact cause of the decreased proliferation 
induced by kaempferol, the effects of kaempferol on the apoptosis of RASFs were investigated by flow cytometry. RASFs (1x105) were cultured in 33‑mm dishes 
in DMEM with DMSO in the presence or absence of kaempferol (100 µM). Following culture for 24 h, the cells were stained with Annexin V and propidium 
iodide (PI) and analyzed by flow cytometry. Kaempferol increased the apoptosis of RASFs compared with the control cells cultured in DMSO without kaemp-
ferol. *P<0.05 vs. no kaempferol.
Figure 3. Kaempferol inhibits interleukin‑1β (IL-1β)‑induced production of matrix metalloproteinases (MMPs) and cyclooxygenase (COX)‑2 in rheuma-
toid arthritis synovial fibroblasts (RASFs). To determine the mRNA and protein expression of MMP‑1, MMP‑3, TIMP‑1 and COX‑1 and COX‑2, RASFs 
(1x106 cells) were cultured for 2 days with/without IL‑1β (1.0 ng/ml) and kaempferol (100 µM). RNA and protein were extracted from the RASFs and analyzed 
by (A) RT‑PCR and (B) western blot analysis. IL‑1β enhanced the protein expression of MMP‑1, MMP‑3, TIMP‑1 and COX‑2 compared with the cells cultured 
without IL‑1β. Kaempferol inhibited the IL‑1β‑induced protein expression of MMP‑1, MMP‑3 and COX‑2. Results are presented as the means ± SD. n=3. 
*P<0.05 or **P<0.01 vs. no IL‑1β and kaempferol, #P<0.05 vs. no IL‑1β and kaempferol, ##P<0.05 vs. IL‑1β without kaempferol.
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Effects of kaempferol on IL-1β-induced MMP, TIMP-1 and 
COX protein expression in RASFs. To determine the protein 
expression of MMPs, TIMP‑1 and COX in the monocultured 
RASFs, we performed western blot analysis. RASFs were 
stimulated with IL‑1β (1.0 ng/ml) for 48 h in the presence or 
absence of kaempferol (100 µM). IL‑1β enhanced the protein 
expression of MMP‑1 and MMP‑3 in RASFs (P<0.05), but 
not that of TIMP‑1; its effects on protein expression were 
similar to those on mRNA expression. Kaempferol inhibited 
the IL‑1β‑induced protein expression of MMP‑1 and MMP‑3 
(P<0.05) (Fig. 3B). IL‑1β also enhanced the protein expres-
sion of COX‑2 in RASFs (p < 0.01), but not that of COX‑1 
(data not shown). Kaempferol inhibited the IL‑1β‑induced 
protein expression of COX‑2 (P<0.05) (Fig. 3B). Kaempferol 
also significantly decreased the protein expression of MMP‑1, 
MMP‑3 and COX‑2 compared with the control cells cultured 
in DMSO without IL‑1β and kaempferol (P<0.05).
Kaempferol inhibits IL-1β-induced PGE2 production in 
RASFs. To confirm the effects of kaempferol on the IL‑1β-
induced production of PGE2 by RASFs, we examined the 
concentration of PGE2 in the culture supernatant. RASFs 
(1x104 cells) were grown in 25 cm2 tissue‑culture flasks 
for 48 h before and after treatment with IL‑1β (1.0 ng/ml) 
and/or kaempferol (100 µM). PGE2 production was increased 
following treatment with IL‑1β (P<0.05) compared with the 
control cells cultured with DMSO without IL‑1β, and it was 
significantly inhibited by treatment with kaempferol at 48 h 
(P<0.05) (Fig. 4); the effects of kaempferol on PGE2 were 
similar to those on COX‑2 expression. Kaempferol also signifi-
cantly decreased the production of PGE2 compared with the 
control cells cultured in DMSO without IL‑1β and kaempferol 
(P<0.05) (Fig. 4).
Effects of kaempferol on IL-1β-induced signaling pathways 
in RASFs. To demonstrate the involvement of the signal trans-
duction pathways and to elucidate the mechanisms behind the 
effects of kaempferol on IL‑1β‑induced RASF proliferation 
and the production of MMPs, COX‑2 and PGE2, the activa-
tion of MAPKs and NF-κB was evaluated in the RASFs. IL‑1β 
phosphorylated intracellular MAPKs, including ERK, p‑38 and 
JNK and kaempferol significantly inhibited the IL‑1β‑induced 
intracellular MAPK activation (Fig. 5A). The activation of 
NF-κB, p65 and the degradation of cytoplasmic IkBα was 
observed in the RASFs treated with IL‑1β. The effects of IL‑1β 
on NF-κB activation were abrogated by kaempferol (Fig. 5B). 
Kaempferol also inhibited the activation of the above intra-
cellular signaling pathways compared with the control cells 
cultured in DMSO without IL‑1β and kaempferol. These results 
indicate that kaempferol inhibits the IL‑1β‑induced prolifera-
tion of RASFs, the expression of COX‑2 and the production of 
PGE2 by inhibiting the activation of intracellular MAPK and 
NF-κB pathways.
Discussion
In this study, we demonstrate that kaempferol induces the 
apoptosis of RASFs and inhibits the IL‑1β‑induced prolifera-
tion of RASFs. It inhibits the activation of the MAPK, ERK1/2, 
p‑38 and JNK and NF-κB signaling pathways, resulting in the 
decreased expression of MMPs and COX‑2, as well as in the 
decreased production of PGE2 by RASFs. These findings 
suggest that kaempferol may be used as a novel therapeutic 
agent for the management of RA by decreasing synovial 
inflammation.
Kaempferol, a polyphenolic flavonoid extracted from fenu-
greek seeds, has been shown to have strong antioxidant and 
anti‑inflammatory properties (18). Previous studies have demon-
strated that kaempferol reduces lipopolysaccharide‑induced 
COX‑2 levels in RAW 264.7 cells (9) and inhibits reactive oxygen 
species production through the inhibition of iNOS and TNF‑α 
protein expression in aged gingival tissues (10). Kaempferol has 
also exhibited anti‑inflammatory effects through the inhibition 
of IL‑4 (11), COX‑2 and CRP expression and the downregulation 
of NF-κB in liver cells (12). Compared with other daily dietary 
flavonols, kaempferol has been reported to be associated with 
a decreased risk of various types of cancer (19‑21). However, 
to our knowledge, there are no reports to date on the effects of 
kaempferol on inflammatory reactions, including the production 
of MMPs, COX‑2 and PGE2 by RASFs and the mechanisms 
involved, which play a crucial role in the pathogenesis of syno-
vitis and articular destruction in RA.
In RA, one of the most striking features is the hyperplasia 
of synovial fibroblasts in the lining layer which is considered 
to be the main mechanism responsible for the hyperplasic 
growth of the RA synovium and eventually destroys articular 
bone and cartilage (22,23). Given that the IL‑1β‑induced 
proliferation of RASFs is closely involved in inflammatory 
synovitis joint destruction, the response of RASFs to IL‑1β 
plays a crucial role in the physiopathology of RA (24). Our 
study demonstrated that kaempferol significantly induced 
the apoptosis of RASFs and inhibited the proliferation of 
unstimulated and IL‑1β‑stimulated of RASFs in a dose‑ and 
time‑dependent manner.
Pro‑inflammatory cytokines, including IL‑1β enhance the 
expression of COX‑2 and MMPs in human RASFs (25,26). 
MMPs are involved in the destruction of the extracellular 
Figure 4. Prostaglandin E2 (PGE2) production was inhibited by treatment with 
kaempferol. Rheumatoid arthritis synovial fibroblasts (RASFs; 1x104 cells) 
were grown in 25 cm2 tissue‑culture flasks for 48 h and were starved serum 
overnight prior to stimulation. RASFs were cultured for 2 days with/without 
interleukin (IL)‑1β (1.0 ng/ml) and kaempferol (100 µM). The production 
of PGE2 by RASFs was evaluated by ELISA. IL‑1β‑induced PGE2 produc-
tion was significantly inhibited by kaempferol. Results are presented as the 
means ± SD, n=3, *,#P<0.05 vs. no IL‑1β and kaempferol, ##P<0.05 vs. IL‑1β 
without kaempferol.
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matrix in articular structures and COX‑2 converts free arachi-
donic acid into prostaglandins, including a variety of bio‑active 
compounds [prostacyclin (PGI2), thromboxane A2 (TXA2), 
PGE2 and prostaglandin D2 (PGD2)]. PGE2, a pleiotropic 
mediator of inflammation, is involved in several pathological 
processes and plays a critical role in eliciting the signs and 
symptoms of inflammation in the joints of RA patients when 
produced in excess (27). We also found that kaempferol 
inhibits the expression of MMPs and COX‑2 and PGE2 
synthesis in a dose‑dependent manner in both unstimulated 
and IL‑1β‑stimulated RASFs. This suggests that kaempferol 
may be a potent therapeutic compound for RA. However, 
further studies are required to investigate the overall effects 
of kaempferol on the pathophysiology of synovitis in in vivo 
systems, such as animal models of RA and collagen‑induced 
arthritis (CIA) and to elucidate the underlying mechanisms.
NF-κB and MAPKs participate in the pathogenic mecha‑-
nisms of inflammation and the destruction of joints in RA. 
It is known that NF-κB, JNK, p‑38 and ERK are expressed 
in cultured RASFs and are readily activated by IL‑1β and 
TNF-α (13,28,29). Numerous studies have demonstrated that 
inhibitors of MAPKs or NF-κB decrease synovial infl amma‑-
tion, bone destruction and cartilage damage in animal models 
of arthritis, including adjuvant arthritis in rats and CIA in 
mice (30,31). It has been described that kaempferol suppresses 
IL-1β‑induced inflammatory responses by regulating signaling 
pathways, including NF-κB activation and MAPK phos‑-
phorylation in human airway epithelial cells (32). In human 
synovial cells, the addition of kaempferol has been shown to 
suppress the TNF‑α‑induced increase in the mRNA expres-
sion of IL‑8 and monocyte chemotactic protein‑1 (MCP‑1) in a 
dose‑dependent manner by inhibiting the activation of NF-κB 
induced by TNF‑α (33). In this study, to elucidate the mecha-
nisms behind the effects of kaempferol on IL‑1β‑induced 
RASF proliferation, the expression of COX‑2 and the produc-
tion of PGE2, as well as the activation of MAPKs and NF-κB 
were examined. Our results revealed that kaempferol inhibited 
the IL‑1β‑induced activation of NF-κB and the phosphoryla‑-
tion of ERK, p‑38 and JNK. However, further investigations 
are required to elucidate the mechanisms by which kaempferol 
suppresses NF-κB activation, which components of NF-κB are 
suppressed, and which intracellular signaling factors are more 
specifically or directly involved in the effects of kaempferol on 
the proliferation of RASFs and PGE2 production.
To our knowledge, this is the first study to report that 
kaempferol induces the apoptosis of RASFs and inhibits the 
IL-1β‑induced proliferation of RASFs. It also suppresses the 
expression of MMP‑1, MMP‑3 and COX‑2 and the production 
of PGE2 by RASFs by inhibiting the IL‑β‑induced activation 
of NF-κB and the phosphorylation of the MAPK pathways, 
Figure 5. Effects of kaempferol on the interleukin‑1β (IL-1β)‑induced activation of mitogen‑activated protein kinase (MAPK) signaling pathways and nuclear 
factor‑κB (NF-κB) activation in rheumatoid arthritis synovial fibroblasts (RASFs). To evaluate the mechanisms behind the effects of kaempferol on IL‑1β in 
RASFs, MAPK signaling pathways (ERK, p38 and JNK) and NF‑κB and IκBα were evaluated by immunoblotting. RASFs were cultured for 10 min with/without 
IL-1β (1.0 ng/ml) and kaempferol (100 µM). IL‑1β enhanced the phosphorylation of ERK, p38 and JNK and kaempferol inhibited the IL‑1β‑induced activation of 
p38 and JNK (A). IL‑1β activated nuclear NF‑κB and decreased cytoplasmic IkBα and kaempferol inhibited the IL‑1β‑induced activation of NF‑κB (B). Results 
are presented as the means ± SD, n=3; *P<0.01 vs. no IL‑1β‑and kaempferol, #P<0.05 vs. IL‑1β without kaempferol.
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p‑38, JNK and ERK. Based on our findings, kaempferol has 
great potential as a novel therapeutic agent and may prove 
useful in the treatment of inflammatory diseases, including 
RA. However, further studies are required to elucidate the 
exact mechanisms underlying the inhibitory effects of kaemp-
ferol on synovial cell proliferation and inflammatory reactions.
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